These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 31018961)

  • 1. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.
    Sabbagh S; Pinal-Fernandez I; Kishi T; Targoff IN; Miller FW; Rider LG; Mammen AL;
    Ann Rheum Dis; 2019 Jul; 78(7):988-995. PubMed ID: 31018961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis.
    Xing X; Li A; Li C
    Respir Med; 2020 Oct; 172():106134. PubMed ID: 32905890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
    Srivastava P; Dwivedi S; Misra R
    Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
    Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
    Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis.
    Vojinovic T; Cavazzana I; Ceruti P; Fredi M; Modina D; Berlendis M; Franceschini F
    Clin Rev Allergy Immunol; 2021 Feb; 60(1):87-94. PubMed ID: 33141387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
    Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF; Levesque H; Jouen F
    Semin Arthritis Rheum; 2012 Jun; 41(6):890-9. PubMed ID: 22078416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
    Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
    Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.
    Shah M; Mamyrova G; Targoff IN; Huber AM; Malley JD; Rice MM; Miller FW; Rider LG;
    Medicine (Baltimore); 2013 Jan; 92(1):25-41. PubMed ID: 23263716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52.
    Yamasaki Y; Satoh M; Mizushima M; Okazaki T; Nagafuchi H; Ooka S; Shibata T; Nakano H; Ogawa H; Azuma K; Maeda A; Tonooka K; Ito H; Takakuwa Y; Inoue M; Mitomi H; Kiyokawa T; Tsuchida K; Matsushita H; Mikage H; Murakami Y; Chan JY; Ozaki S; Yamada H
    Mod Rheumatol; 2016; 26(3):403-9. PubMed ID: 26344678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.
    Temmoku J; Sato S; Fujita Y; Asano T; Suzuki E; Kanno T; Furuya MY; Matsuoka N; Kobayashi H; Watanabe H; Koga T; Shimizu T; Kawakami A; Migita K
    Medicine (Baltimore); 2019 May; 98(20):e15578. PubMed ID: 31096460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
    Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
    J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F; Li S; Wang T; Shi J; Wang G
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody.
    Sclafani A; D'Silva KM; Little BP; Miloslavsky EM; Locascio JJ; Sharma A; Montesi SB
    Respir Res; 2019 Nov; 20(1):256. PubMed ID: 31718649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature.
    Labirua-Iturburu A; Selva-O'Callaghan A; Vincze M; Dankó K; Vencovsky J; Fisher B; Charles P; Dastmalchi M; Lundberg IE
    Medicine (Baltimore); 2012 Jul; 91(4):206-211. PubMed ID: 22732951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease.
    Gui X; Shenyun S; Ding H; Wang R; Tong J; Yu M; Zhao T; Ma M; Ding J; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4570-4578. PubMed ID: 35148366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features associated with the presence of anti-Ro52 and anti-Ro60 antibodies in Jo-1 antibody-positive anti-synthetase syndrome.
    Yamaguchi K; Tang Q; Poland P; Reay DP; Gregory A; Aggarwal R; Oddis CV; Ascherman DP
    Front Immunol; 2024; 15():1399451. PubMed ID: 38895121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies.
    Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G
    J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.